Literature DB >> 28548646

Prevalence and the risk factors for visual impairment in age-related macular degeneration.

S Srinivasan1, G Swaminathan1, V Kulothungan1, R Raman1, T Sharma1.   

Abstract

PurposeTo characterize the type, and the causes of visual impairment (VI) in various stages of early and late age-related macular degeneration (AMD) and the factors associated with visual impairment in subjects with AMDMethods6617 subjects ≥60 years were enumerated; 5495 (83.04%) participated in eye examination. Of which, 4791 subjects had gradable fundus images. AMD was graded per International ARM Epidemiological Study Group. Subjects underwent detailed ophthalmic exam. VI was defined per the WHO classification. Mild VI was defined as VA less than 6/12 to 6/18, moderate VI-VA less than 6/18 but up to 6/60, severe VI-VA less than 6/60 but up to 3/60 and legal blindness-VA worse than 3/60. Factors associated with VI in AMD was analyzed with univariate and logistic regression analysis.ResultsNine hundred and eighty-eight subjects were identified as having AMD (893 with early AMD and 95 with late AMD); 85% of the subjects (95% CI: 82.7-87.1) had no VI, 13.1% had mild VI (95% CI: 11.1-15.3), 0.8% had severe VI (95% CI: 0.4-1.6), 1.1% had legal blindness (95% CI: 0.6-1.9). Prevalence of any VI was 13.7% in early AMD and 27.4% in late AMD, P=0.0004; age group 65-70 years (OR=1.89, 95% CI: 1.16-3.08, P=0.011), and those ≥75 years (OR=3.67, 95% CI: 1.95-6.91, P=0.0001) had greater odds of VI compared with age group 60-64 years. Male gender was a protective factor for VI (OR=0.57, CI: 0.36-0.90, P=0.016). Cataract (31.8%) and refractive error (28.4%) accounted for a majority of the VI.ConclusionsCataract and refractive error account for a significant proportion of VI in the south Indian population with AMD. Early AMD is the third leading cause of VI. Greater age and female gender are associated with VI in subjects with AMD.

Entities:  

Mesh:

Year:  2017        PMID: 28548646      PMCID: PMC5518841          DOI: 10.1038/eye.2017.72

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  41 in total

1.  Vision and mobility performance of subjects with age-related macular degeneration.

Authors:  Shirin E Hassan; Jan E Lovie-Kitchin; Russell L Woods
Journal:  Optom Vis Sci       Date:  2002-11       Impact factor: 1.973

Review 2.  The epidemiology of age-related macular degeneration in the Indian subcontinent.

Authors:  Jyh Haur Woo; Srinivasan Sanjay; Kah-Guan Au Eong
Journal:  Acta Ophthalmol       Date:  2008-11-12       Impact factor: 3.761

3.  Macular function impairment in eyes with early age-related macular degeneration.

Authors:  E Midena; C Degli Angeli; M C Blarzino; M Valenti; T Segato
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-02       Impact factor: 4.799

4.  Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study.

Authors:  C C Klaver; R C Wolfs; J R Vingerling; A Hofman; P T de Jong
Journal:  Arch Ophthalmol       Date:  1998-05

5.  Visual impairment in Australia: distance visual acuity, near vision, and visual field findings of the Melbourne Visual Impairment Project.

Authors:  H R Taylor; P M Livingston; Y L Stanislavsky; C A McCarty
Journal:  Am J Ophthalmol       Date:  1997-03       Impact factor: 5.258

6.  The prevalence of age-related maculopathy: the visual impairment project.

Authors:  M R VanNewkirk; M B Nanjan; J J Wang; P Mitchell; H R Taylor; C A McCarty
Journal:  Ophthalmology       Date:  2000-08       Impact factor: 12.079

Review 7.  Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study.

Authors:  P Mitchell; W Smith; K Attebo; J J Wang
Journal:  Ophthalmology       Date:  1995-10       Impact factor: 12.079

8.  Visual impairment of age-related macular degeneration. An epidemiological study of 1000 aged individuals.

Authors:  T Vinding
Journal:  Acta Ophthalmol (Copenh)       Date:  1990-04

Review 9.  Age-related eye disease and gender.

Authors:  Madeleine Zetterberg
Journal:  Maturitas       Date:  2015-10-23       Impact factor: 4.342

10.  Binocular visual-field loss increases the risk of future falls in older white women.

Authors:  Anne L Coleman; Steven R Cummings; Fei Yu; Gergana Kodjebacheva; Kristine E Ensrud; Peter Gutierrez; Katie L Stone; Jane A Cauley; Kathryn L Pedula; Marc C Hochberg; Carol M Mangione
Journal:  J Am Geriatr Soc       Date:  2007-03       Impact factor: 5.562

View more
  5 in total

1.  A comparison of risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese patients.

Authors:  Xiao-Li Chen; Qin-Rui Hu; Yu-Jing Bai; Yu Deng; Hai-Wei Wang; Shan Liu; Yin-Lin Wang; Yan-Kun Yue
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-01       Impact factor: 3.117

2.  Gender variation in central serous chorioretinopathy.

Authors:  Daren Hanumunthadu; Elon H C Van Dijk; Sankeert Gangakhedkar; Abhilash Goud; Chui Ming Gemmy Cheung; Daniel Cherfan; Chintan Sarvaiya; Alay Banker; Catherine Meyerle; Camiel J Boon; Rishi Singh; Lihteh Wu; Jay Chhablani
Journal:  Eye (Lond)       Date:  2018-07-09       Impact factor: 3.775

3.  Association Between Geographic Distribution of Eye Care Clinicians and Visual Impairment in California.

Authors:  Karissa M Wang; Victoria L Tseng; Xiongfei Liu; Deyu Pan; Fei Yu; Richard Baker; Bartly J Mondino; Anne L Coleman
Journal:  JAMA Ophthalmol       Date:  2022-06-01       Impact factor: 8.253

4.  Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor.

Authors:  Mayur Choudhary; Stephen Safe; Goldis Malek
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-02-23       Impact factor: 5.187

5.  Prevalence and sociodemographic factors associated with vision difficulties in Ghana, Gambia, and Togo: a multi-country analysis of recent multiple Indicator cluster surveys.

Authors:  Abdul-Aziz Seidu; Pascal Agbadi; Precious Adade Duodu; Nutifafa Eugene Yaw Dey; Henry Ofori Duah; Bright Opoku Ahinkorah
Journal:  BMC Public Health       Date:  2021-11-24       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.